As of 3:13:52 PM EST. Market Open.
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
8,686.0000
20,968.0000
41,867.0000
23,028.0000
135,082.0000
Cost of Revenue
1,228.0000
6,174.0000
7,266.0000
--
--
Gross Profit
7,458.0000
14,794.0000
34,601.0000
23,028.0000
135,082.0000
Operating Expense
87,336.0000
136,289.0000
122,136.0000
112,111.0000
129,697.0000
Operating Income
-79,878.0000
-121,495.0000
-87,535.0000
-89,083.0000
5,385.0000
Net Non Operating Interest Income Expense
-6,456.0000
-604.0000
--
--
--
Other Income Expense
-9,191.0000
3,586.0000
2,061.0000
642.0000
2,334.0000
Pretax Income
-95,525.0000
-118,513.0000
-85,474.0000
-88,441.0000
7,719.0000
Tax Provision
--
--
--
--
-691.0000
Net Income Common Stockholders
-95,525.0000
-118,513.0000
-85,474.0000
-88,441.0000
8,410.0000
Diluted NI Available to Com Stockholders
-95,525.0000
-118,513.0000
-85,474.0000
-88,441.0000
8,410.0000
Basic EPS
-1.75
-2.19
-1.59
-1.74
0.18
Diluted EPS
-1.75
-2.19
-1.59
-1.74
0.18
Basic Average Shares
54,659.8770
54,149.0590
53,653.5640
50,718.7650
47,413.2500
Diluted Average Shares
54,659.8770
54,149.0590
53,653.5640
50,718.7650
47,915.0300
Total Operating Income as Reported
-85,567.0000
-121,495.0000
-87,535.0000
-89,083.0000
5,385.0000
Total Expenses
88,564.0000
142,463.0000
129,402.0000
112,111.0000
129,697.0000
Net Income from Continuing & Discontinued Operation
-95,525.0000
-118,513.0000
-85,474.0000
-88,441.0000
8,410.0000
Normalized Income
-83,053.0000
-118,513.0000
-85,474.0000
-88,441.0000
8,410.0000
Interest Expense
6,456.0000
604.0000
--
--
--
Net Interest Income
-6,456.0000
-604.0000
--
--
--
EBIT
-89,069.0000
-117,909.0000
-85,474.0000
-88,441.0000
5,385.0000
EBITDA
-88,795.0000
-117,650.0000
-85,226.0000
-88,193.0000
5,594.0000
Reconciled Cost of Revenue
1,135.0000
6,045.0000
7,146.0000
--
--
Reconciled Depreciation
274.0000
259.0000
248.0000
248.0000
209.0000
Net Income from Continuing Operation Net Minority Interest
-95,525.0000
-118,513.0000
-85,474.0000
-88,441.0000
8,410.0000
Total Unusual Items Excluding Goodwill
-12,472.0000
--
--
--
--
Total Unusual Items
-12,472.0000
--
--
--
--
Normalized EBITDA
-76,323.0000
-117,650.0000
-85,226.0000
-88,193.0000
5,594.0000
Tax Rate for Calcs
--
--
--
--
0.0003
12/31/2020 - 1/31/2014
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
APTO Aptose Biosciences Inc.
0.2367
-1.75%
COEP Coeptis Therapeutics Holdings, Inc.
0.1546
-15.15%
REVB Revelation Biosciences, Inc.
0.3963
+10.42%
CDT Conduit Pharmaceuticals Inc.
0.0760
+26.46%
SLGL Sol-Gel Technologies Ltd.
1.0800
-3.57%
VIRX Viracta Therapeutics, Inc.
0.1619
+1.19%
MTEM Molecular Templates, Inc.
0.0461
+9.76%
LYRA Lyra Therapeutics, Inc.
0.2218
+16.43%
PTIX Protagenic Therapeutics, Inc.
0.5168
-6.88%
VINC Vincerx Pharma, Inc.
0.3250
+66.80%